Ildong Pharmaceutical’s challenge to market with its first novel chronic hepatitis B treatment ‘Besivo’ on 1 Nov
‘Besivo,’ the Ildong Pharmaceutical’s(CEO Woong-Sup Yoon) first novel drug and the Korea’s 28th novel drug, will be launched with the National Health Insurance benefit on 1 November. Its insurance benefit will be KRW 3,403 per tablet confirmed by the Ministry of Health and Welfare’s(MOHW) officia...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
